Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

EU brings forward Pfizer/BioNTech COVID shot for younger children to Dec 13

Stock MarketsDec 01, 2021 14:22
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: A medical worker prepares a dose of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine at a coronavirus disease (COVID-19) vaccination center in Madrid, Spain, November 24, 2021. REUTERS/Sergio Perez/ 2/2

By Andreas Rinke and Ludwig Burger

FRANKFURT (Reuters) -The European Union-wide rollout of Pfizer (NYSE:PFE) and BioNTech's COVID-19 vaccine version for five- to 11-year-old children will begin Dec 13, one week earlier than previously planned, Germany's health ministry said on Wednesday.

"Given the current pandemic situation, this is good news for parents and children. Many are awaiting this eagerly," acting health minister Jens Spahn said in the statement.

Germany is due to receive 2.4 million doses for use as a two-dose regimen, the ministry said, adding it has commitment on the new date from the manufacturer.

Germany's regional health ministers on Monday agreed to prepare for the launch, with offerings such as family sections within vaccination centres.

A BioNTech spokesperson confirmed the earlier start, adding it was contingent on the production batch passing quality control checks early next week.

The rollout will be brought forward without an impact on agreed delivery volumes thanks to "a massive effort including weekend work" on the part of Pfizer and BioNTech staff, the company added.

It said that while BioNTech had been in discussions with the EU Commission about the pandemic situation, it had not received a direct request for faster delivery. An EU official confirmed that the Commission had not prompted the move.

The EU last week approved use of the low-dose vaccine version for five- to 11-year-olds, following authorisation in May to give the standard adult dosage to children 12 years and older.

Pent-up demand for a shot for the youngest has been palpable in some countries. In hard-hit Austria, where the government has reimposed a nationwide lockdown, some provinces have been vaccinating five to 11-year-old children with a lower dose of the adult vaccine even before the EU recommendation.

Denmark followed suit with that method on Sunday, saying there was no time to lose amid rising infections among the youngest.

Coronavirus is spreading faster in Europe than in other world regions, prompting a scramble to persuade non-vaccinated adults to get shots, to get a campaign for third booster doses off the ground and to inoculate children.

Uncertainty over Omicron, the highly contagious new variant first detected in South Africa, has added urgency to the fight against the pandemic on many fronts.

Recorded infections among school-age children in Germany have surged and have been about twice as high as the all-age average over the last few weeks.

Frequent testing in classrooms may be bringing more asymptomatic cases to light than in the overall population.

The United States started distributing the paediatric version of the Pfizer shot in early November, followed by Canada in mid-November.

EU brings forward Pfizer/BioNTech COVID shot for younger children to Dec 13
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email